FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205645249> ?p ?o ?g. }

• W4205645249 endingPage "81" @default.
• W4205645249 startingPage "81" @default.
• W4205645249 abstract "81 Background: Patients undergoing adjuvant treatment with FOLFOX for colorectal cancer (CRC) are at risk of developing chemotherapy-induced neutropenia (CIN). We assessed survival outcomes in patients who develop CIN in this setting. Methods: We performed a retrospective chart review of patients with CRC treated with FOLFOX at our institution in Canada from 2013 to 2015. The survival follow-up cut-off date was August 2021. Demographic, treatment, and outcome data were collected. CIN was defined as ANC <1.5, and all episodes of neutropenia were assumed to be the result of chemotherapy. Median OS was calculated using Kaplan-Meier product limit estimates. Results: A total of 302 patients were included (baseline demographics in the table). Median follow-up was 110 months. In the overall cohort, 174 patients (58%) had at least one episode of CIN. CIN occurred in 56% of those with stage II cancer, 43% of those with low risk stage III cancer (T1-3 and N1), and 45% of those with high risk stage III cancer (T4 or N2). Median time to first CIN event was 4.3 months. Among patients with at least one episode of CIN, the first CIN event occurred during the first 3 months of treatment in 110 (63%). Among patients with at least one episode of CIN, 79 (45%) received subsequent granulocyte colony-stimulating factor (GCSF). The median OS in the overall cohort was 171 months. For patients with and without CIN the median OS had not been reached, HR 0.84 (95% CI 0.55-1.29, p=0.43). The median OS for patients with CIN treated with and without GCSF had not been reached, HR 1.02 (95% CI 0.57-1.82, p=0.94). The 5-year survival rate for patients with and without CIN was 87% vs 77%. The 10-year survival rate for patients with and without CIN was 70% vs 64%. A trend toward improved survival in those with CIN remained when results were analyzed by cancer stage. Conclusions: Patients with CIN had a trend toward improved survival compared to those who did not have CIN. There was no indication that GCSF in the setting of CIN impacted survival. The causes for the potentially protective effect of CIN in the setting of adjuvant CRC treatment require further elucidation.[Table: see text]" @default.
• W4205645249 created "2022-01-26" @default.
• W4205645249 creator A5014239053 @default.
• W4205645249 creator A5016636327 @default.
• W4205645249 creator A5023500477 @default.
• W4205645249 creator A5025676609 @default.
• W4205645249 creator A5039428870 @default.
• W4205645249 creator A5074884162 @default.
• W4205645249 creator A5088918450 @default.
• W4205645249 date "2022-02-01" @default.
• W4205645249 modified "2023-09-24" @default.
• W4205645249 title "Survival outcomes associated with chemotherapy-induced neutropenia in the adjuvant treatment of colorectal cancer with FOLFOX." @default.
• W4205645249 doi "https://doi.org/10.1200/jco.2022.40.4_suppl.081" @default.
• W4205645249 hasPublicationYear "2022" @default.
• W4205645249 type Work @default.
• W4205645249 citedByCount "0" @default.
• W4205645249 crossrefType "journal-article" @default.
• W4205645249 hasAuthorship W4205645249A5014239053 @default.
• W4205645249 hasAuthorship W4205645249A5016636327 @default.
• W4205645249 hasAuthorship W4205645249A5023500477 @default.
• W4205645249 hasAuthorship W4205645249A5025676609 @default.
• W4205645249 hasAuthorship W4205645249A5039428870 @default.
• W4205645249 hasAuthorship W4205645249A5074884162 @default.
• W4205645249 hasAuthorship W4205645249A5088918450 @default.
• W4205645249 hasConcept C121608353 @default.
• W4205645249 hasConcept C126322002 @default.
• W4205645249 hasConcept C141071460 @default.
• W4205645249 hasConcept C167135981 @default.
• W4205645249 hasConcept C2776694085 @default.
• W4205645249 hasConcept C2777063308 @default.
• W4205645249 hasConcept C2778260052 @default.
• W4205645249 hasConcept C2780962732 @default.
• W4205645249 hasConcept C50382708 @default.
• W4205645249 hasConcept C526805850 @default.
• W4205645249 hasConcept C71924100 @default.
• W4205645249 hasConcept C72563966 @default.
• W4205645249 hasConceptScore W4205645249C121608353 @default.
• W4205645249 hasConceptScore W4205645249C126322002 @default.
• W4205645249 hasConceptScore W4205645249C141071460 @default.
• W4205645249 hasConceptScore W4205645249C167135981 @default.
• W4205645249 hasConceptScore W4205645249C2776694085 @default.
• W4205645249 hasConceptScore W4205645249C2777063308 @default.
• W4205645249 hasConceptScore W4205645249C2778260052 @default.
• W4205645249 hasConceptScore W4205645249C2780962732 @default.
• W4205645249 hasConceptScore W4205645249C50382708 @default.
• W4205645249 hasConceptScore W4205645249C526805850 @default.
• W4205645249 hasConceptScore W4205645249C71924100 @default.
• W4205645249 hasConceptScore W4205645249C72563966 @default.
• W4205645249 hasIssue "4_suppl" @default.
• W4205645249 hasLocation W42056452491 @default.
• W4205645249 hasOpenAccess W4205645249 @default.
• W4205645249 hasPrimaryLocation W42056452491 @default.
• W4205645249 hasRelatedWork W1330306 @default.
• W4205645249 hasRelatedWork W1849033 @default.
• W4205645249 hasRelatedWork W265120 @default.
• W4205645249 hasRelatedWork W3819646 @default.
• W4205645249 hasRelatedWork W4112738 @default.
• W4205645249 hasRelatedWork W5279832 @default.
• W4205645249 hasRelatedWork W5346711 @default.
• W4205645249 hasRelatedWork W614665 @default.
• W4205645249 hasRelatedWork W24504552 @default.
• W4205645249 hasRelatedWork W3109140 @default.
• W4205645249 hasVolume "40" @default.
• W4205645249 isParatext "false" @default.
• W4205645249 isRetracted "false" @default.
• W4205645249 workType "article" @default.